Reported Earlier, ARCA Biopharma Updates Special Dividend To $1.613/Share In Preparation For Oruka Therapeutics Merger
Reported Earlier, ARCA Biopharma Updates Special Dividend To $1.613/Share In Preparation For Oruka Therapeutics Merger
ARCA biopharma updates the previously announced final amount of the special cash dividend (the "Special Dividend"), which will now equal $1.613 per share of ARCA's common stock, payable on August 28, 2024, to ARCA's stockholders of record as of August 26, 2024. The Special Dividend was declared by ARCA's Board of Directors on August 16, 2024, in connection with the previously announced merger (the "Merger") with Oruka Therapeutics, Inc. ("Oruka"), pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the "Merger Agreement"). The exact amount of the Special Dividend was calculated in accordance with the Merger Agreement and based on ARCA's reasonable, good faith approximation of the amount by which ARCA's net cash, as determined prior to the closing of the Merger, will exceed $5,000,000.
方舟生物醫藥更新了先前宣佈的特別現金股息（「特別股息」）的最終金額，現在將爲每股方舟生物醫藥普通股支付1.613美元，於2024年8月28日支付給方舟生物醫藥的股東，2024年8月26日爲止。特別股息由方舟生物醫藥的董事會於2024年8月16日宣佈，與之前宣佈的與Oruka Therapeutics, Inc.（以下簡稱「Oruka」）的合併（以下簡稱「合併」）相關，根據於2024年4月3日簽署的合併與重組協議（以下簡稱「合併協議」）。特別股息的確切金額根據合併協議並基於方舟生物醫藥合併完成之前方舟生物醫藥淨現金金額超過5,000,000美元的合理、善意估計計算而得。
